麦斯莫医疗 2026年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April4, 2026OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________Commission File Number 001-33642________________________________________________ MASIMO CORPORATION (Exact Name of Registrant as Specified in its Charter)________________________________________________ 33-0368882(I.R.S. EmployerIdentification Number)92618(Zip Code) Delaware(State or Other Jurisdiction ofIncorporation or Organization)52 DiscoveryIrvine,California(Address of Principal Executive Offices) (949)297-7000 (Registrant’s Telephone Number, Including Area Code) Securities Registered pursuant to Section 12(b) of the Act: Trading Symbol(s) Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or15(d) of the Securities Exchange Act of 1934 during the preceding 12months (or for such shorter period thatthe registrant was required to file such reports), and (2)has been subject to such filing requirements for thepast 90days. Indicate by check mark whether the registrant has submitted electronically every Interactive Data File requiredto be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12months (or for such shorter period that the registrant was required to submit such files). Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reportingcompany,” and “emerging growth company” in Rule12b-2 of the Exchange Act. Large acceleratedfiler☒Non-accelerated filer☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the ExchangeAct.) Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:Number of Shares Outstanding as of Commonstock,$0.001parvalue MASIMO CORPORATIONFORM 10-Q FOR THE QUARTER ENDED APRIL4, 2026TABLE OF CONTENTS PARTI. Financial Information Item1.Financial Statements (unaudited):Condensed Consolidated Balance Sheets as of April 4, 2026 and January 3, 2026Condensed Consolidated Statements of Operations for the three months ended April 4, 2026 and March29, 2025Condensed Consolidated Statements of Comprehensive Income (Loss) for the three months ended April4, 2026 and March 29, 2025Condensed Consolidated Statements of Stockholders’ Equity for the three months ended April 4, 2026and March 29, 2025Condensed Consolidated Statements of Cash Flows for the three months ended April 4, 2026 and March29, 2025Notes to Condensed Consolidated Financial StatementsItem2.Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem3.Quantitative and Qualitative Disclosures About Market RiskItem4.Controls and ProceduresPARTII. Other InformationItem1.Legal ProceedingsItem1A.Risk FactorsItem 5.Other InformationItem6.ExhibitsSignatures PART I. FINANCIAL INFORMATION MASIMO CORPORATIONCONDENSED CONSOLIDATED BALANCE SHEETS(unaudited, in millions, except par values) MASIMO CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(unaudited, in millions, except per share amounts) MASIMO CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)(unaudited, in millions) The accompanying notes are an integral part of these condensed consolidated financial statements. MASIMO CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(unaudited, in millions) Table of Contents MASIMO CORPORATIONNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(unaudited) 1. Description of the Company Masimo Corporation (the “Company”) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, and patient monitors. Powered by the Masimo HospitalAutomationand Masimo SafetyNet platforms, Masimo connectivity, automation, and telehealth and telemonitoring solutions areimproving and automating care delivery both in the hospital and beyond. As of April4, 2026, the Company operates one reportablesegment: healthcare.™® The Company’s healthcare products and patient monitoring solutions generally incorporate a monitor or circuit board, proprietarysingle-patient use or reusable sensors, software and/or cables. The Company primarily sells its healthcare products to hospitals,emergency medical service providers, home care providers, physic